Translational gaps and clinical readiness of artificial intelligence and multimodal imaging in breast cancer diagnostics
Open Access
- 19 July 2026
- journal article
- review article
- Published by Springer Nature in Discover Oncology
- Vol. 17 (1)
Abstract
Background: A persistent translational gap separates the high research-benchmark performance of artificial intelligence (AI) and advanced imaging in breast cancer from demonstrated real-world clinical utility. Most systems reporting accuracy above 95% on curated datasets have not been externally validated across diverse populations and imaging platforms. Purpose: We critically examine AI-driven diagnostics and advanced imaging modalities for breast cancer, focusing on the barriers—generalization failure, algorithmic bias, reproducibility, and workflow integration—that determine clinical readiness rather than on benchmark capability alone. Methods: We conducted a structured review of peer-reviewed literature (January 2015–March 2025) across PubMed, Scopus, IEEE Xplore, and Web of Science, combining breast cancer terms with AI, deep learning, vision transformers, digital breast tomosynthesis (DBT), contrast-enhanced mammography (CEM), MRI, and liquid biopsy. Study selection followed an explicit, PRISMA-style screening workflow; 127 of 312 identified records met predefined eligibility and quality criteria. Results: Reported benchmark performance is consistently optimistic relative to clinical performance: deep learning exceeds 95% accuracy and vision transformers report near-perfect classification on CBIS-DDSM, yet a reproducible 5–15% degradation follows deployment owing to distribution shift, scanner and vendor heterogeneity, and population differences. Among validated technologies, DBT raises cancer detection by 27% while lowering false positives; CEM increases sensitivity from 71.5% to 92.7% in dense breasts; and the Mirai risk model (AUC 0.76−0.81) outperforms traditional clinical tools. Liquid biopsy offers high-specificity molecular profiling but inadequate sensitivity (33%) for population screening. Critically, technical maturity is decoupled from validation depth and equity readiness—the dimensions that actually gate adoption. Conclusion: Realizing the potential of AI-augmented, risk-stratified screening requires multicenter prospective and multi-vendor external validation, fairness-aware design with subgroup reporting, transparent reproducibility, and adaptive regulation of continuously learning systems. We propose an operationally defined translational readiness framework that scores each technology along six dimensions, locating it on the continuum from research capability to equitable clinical deployment.Keywords
This publication has 52 references indexed in Scilit:
- Mammo-CLIP: A Vision Language Foundation Model to Enhance Data Efficiency and Robustness in Mammography2024
- Contrast-enhanced mammography: past, present, and futureClinical Imaging, 2020
- Will traditional biopsy be substituted by radiomics and liquid biopsy for breast cancer diagnosis and characterisation?Medical Oncology, 2020
- Digital breast tomosynthesis for breast cancer detection: a diagnostic test accuracy systematic review and meta-analysisEuropean Radiology, 2020
- Contrast‐enhanced MRI for breast cancer screeningJournal of Magnetic Resonance Imaging, 2019
- Methylation analysis of plasma cell-free DNA for breast cancer early detection using bisulfite next-generation sequencingTumor Biology, 2016
- Plasma DNA integrity index as a potential molecular diagnostic marker for breast cancerTumor Biology, 2015
- Diagnostic performance of dual-energy contrast-enhanced subtracted mammography in dense breasts compared to mammography alone: interobserver blind-reading analysisEuropean Radiology, 2014
- Prospective trial comparing full-field digital mammography (FFDM) versus combined FFDM and tomosynthesis in a population-based screening programme using independent double reading with arbitrationEuropean Radiology, 2013
- INbreastAcademic Radiology, 2012